INDIANAPOLIS, Nov. 12, 2012 /PRNewswire/ -- Roche Diagnostics, a world leader in pharmaceuticals and diagnostics, announced in June its plans to invest $300 million during the next 10 years in expanding its North American headquarters located on the northeast side of Indianapolis. The first phase of the project is a new Learning and Development Center, where approximately 1,500 customers from across the nation will be trained each year.
Mayor Greg Ballard will be joined by Roche Diagnostics President and CEO Jack Phillips along with members of the City-County Council and community leaders to break ground on the expansion and unveil renderings of the new building, which will have a distinct architectural style. WHO: Mayor Greg BallardJack Phillips, President and CEO, Roche DiagnosticsMembers of City-County CouncilWHEN:Wednesday, November 14, 201210:00 A.M. Eastern Standard TimeWHAT:Groundbreaking Ceremony for Roche Diagnostics Learning and Development CenterWHERE:Roche Diagnostics Campus – Near Entrance 49115 Hague Road, Indianapolis, IndianaRSVP:Please RSVP to Jacque Robertson at firstname.lastname@example.org or (317) 521-2819Due to limited parking on corporate campus, RSVPs are appreciated.NOTE:Press riser with mult box to be provided. Principals will be made available to press following event. About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.
All trademarks used or mentioned in this release are protected by law.For further information, please contact: Todd Siesky Director, Corporate Communications
Indianapolis, IN(317) 521-3966 O
(317) 361-7637 Ctodd.email@example.com
|SOURCE Roche Diagnostics, Inc.|
Copyright©2012 PR Newswire.
All rights reserved